anti-tau antibodies

Roche, AC Immune attempt to flesh out anti-tau Alzheimer's data, but the forecast remains cloudy
Roche, AC Immune attempt to flesh out anti-tau Alzheimer's data, but the forecast remains cloudy
Endpoints
AC Immune
Roche
anti-tau antibodies
Alzheimer's disease
Flag link:
Roche doubles down on Tau
Roche doubles down on Tau
EP Vantage
Roche
anti-tau antibodies
UCB Pharma
UCB01017
Alzheimer's disease
Flag link:
Neuroscience biotech led by former Pfizer crew wins $17M to target toxic tau
Neuroscience biotech led by former Pfizer crew wins $17M to target toxic tau
Endpoints
Neurosciences
anti-tau antibodies
Pinteon Therapeutics
Flag link:
AbbVie scraps an anti-tau study, and that may foretell more big trouble for a beleaguered Biogen
AbbVie scraps an anti-tau study, and that may foretell more big trouble for a beleaguered Biogen
Endpoints
AbbVie
Biogen
anti-tau antibodies
ABBV-8E12
progressive supranuclear palsy
Flag link:
Prothena, Celgene ink neuro R&D pact potentially worth $2B+
Prothena, Celgene ink neuro R&D pact potentially worth $2B+
Fierce Biotech
Prothena
Celgene
R&D
TDP-43
anti-tau antibodies
Alzheimer's disease
Flag link:
Right on the heels of a PhIII failure, Merck neuroscience doubles down with a new drug targeting tau
Right on the heels of a PhIII failure, Merck neuroscience doubles down with a new drug targeting tau
Endpoints
Merck
Neuroscience
anti-tau antibodies
R&D
drug development
Flag link:
AbbVie’s Anti-Tau Antibody Enters Phase II Clinical Trials for Alzheimer’s Disease
AbbVie’s Anti-Tau Antibody Enters Phase II Clinical Trials for Alzheimer’s Disease
Xtalks
AbbVie
clinical trials
anti-tau antibodies
Alzheimer's disease
ABBV-8E12
Flag link:
FDA grants AbbVie's anti-tau drug orphan status
FDA grants AbbVie's anti-tau drug orphan status
BioPharma Dive
FDA
AbbVie
anti-tau antibodies
ABBV-8E12
progressive supranuclear palsy
C2N Diagnostics
Flag link: